[14C]ontunisertib

Phase 1

AAgomab Spain S.L.U.

[14C]ontunisertib is one of 3 therapeutic programs targeting Fibrostenotic Crohn's Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Fibrostenotic Crohn's DiseaseNot yet recruiting

Fibrostenotic Crohn's DiseasePhase 1

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Fibrostenotic Crohn's Disease

#DrugCompanyPhaseTrials

Ontunisertib

AAgomab Spain S.L.U.

Phase 2

2 2

AGMB-129

AAgomab Spain S.L.U.

Phase 2

1 3

[14C]ontunisertib

AAgomab Spain S.L.U.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Not yet recruiting

Fibrostenotic Crohn's Disease

NCT07672574

Clinical

Trials by Indication[1]

Fibrostenotic Crohn's Disease1 trial

An Open-label, Two-part Trial to Assess the Mass-balance Recovery, Metabolite Profile, Metabolite Identification and Absolute Bioavailability of [14C] Ontunisertib in Healthy Male Participants

Not yet recruiting·AAgomab Spain S.L.U.·Phase 1·NCT07672574·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for [14C]ontunisertib. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for [14C]ontunisertib. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Agomab Spain S.L.U. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: AAgomab Spain S.L.U.

[14C]ontunisertib

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Fibrostenotic Crohn's Disease1 trial

References

Drug Info

Quick Facts

Related News